暴露前预防（PrEP）用于预防 HIV 感染的临时指南更新：为注射吸毒者提供 PrEP。
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
出版信息
MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):463-5.
Abstract
On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs.
摘要
2013 年 6 月 12 日，泰国卫生部和疾病预防控制中心发布了一项关于每日口服 300 毫克替诺福韦酯富马酸二异丙酯（TDF）的随机对照试验结果，该试验表明该药物可有效降低注射吸毒者（IDUs）感染人类免疫缺陷病毒（HIV）的风险（1）。基于这些发现，疾病预防控制中心建议将暴露前预防（PrEP）作为通过注射非法药物感染 HIV 的高危人群的几种预防选择之一。
相似文献
1
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):463-5.
2
Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
JAMA. 2014;312(4):362-71. doi: 10.1001/jama.2014.8735.
3
Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471.
4
Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Lancet Infect Dis. 2014 Nov;14(11):1055-1064. doi: 10.1016/S1473-3099(14)70937-5. Epub 2014 Oct 7.
5
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222.
6
Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
Ann Pharmacother. 2014 Apr;48(4):507-18. doi: 10.1177/1060028014520880. Epub 2014 Jan 28.
7
Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
Drugs. 2013 Mar;73(3):279-91. doi: 10.1007/s40265-013-0024-4.
8
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
Ann Intern Med. 2012 Oct 2;157(7):490-7. doi: 10.7326/0003-4819-157-7-201210020-00510.
9
Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2(0 2):S130-4. doi: 10.1097/QAI.0b013e3182986fac.
10
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
Antimicrob Agents Chemother. 2011 Oct;55(10):4905-7. doi: 10.1128/AAC.00120-11. Epub 2011 Jul 25.
引用本文的文献
1
Investigating facilitators and barriers to the routine provision of HIV PrEP in community pharmacies in London.
BMC Health Serv Res. 2025 Feb 25;25(1):312. doi: 10.1186/s12913-025-12336-1.
2
Facilitators and Barriers to Implementing HIV Testing and Pre-Exposure Prophylaxis in Substance Use Treatment Programs: Perspectives of Non-medical Staff.
Subst Use Addctn J. 2024 Oct;45(4):548-558. doi: 10.1177/29767342241274077. Epub 2024 Sep 5.
3
Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17-24 Years Old in the USA.
Sex Res Social Policy. 2022 Dec;19(4):1944-1953. doi: 10.1007/s13178-022-00740-9. Epub 2022 Jun 8.
4
Evidence of Potential Discriminatory HIV Pre-Exposure Prophylaxis (PrEP) Prescribing Practices for People Who Inject Drugs Among a Small Percentage of Providers in the U.S.
J Prim Care Community Health. 2022 Jan-Dec;13:21501319211063999. doi: 10.1177/21501319211063999.
5
HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018.
Subst Use Misuse. 2020;55(14):2409-2419. doi: 10.1080/10826084.2020.1823419. Epub 2020 Sep 23.
6
A Narrative Review of Continuing Professional Development Needs for Pharmacists with Respect to Pre-exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV).
Pharmacy (Basel). 2020 May 11;8(2):84. doi: 10.3390/pharmacy8020084.
7
Associations between recent thymic emigrants and CD4+ T-cell recovery after short-term antiretroviral therapy initiation.
AIDS. 2020 Mar 15;34(4):501-511. doi: 10.1097/QAD.0000000000002458.
8
Current US Guidelines for Prescribing HIV Pre-exposure Prophylaxis (PrEP) Disqualify Many Women Who Are at Risk and Motivated to Use PrEP.
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):395-405. doi: 10.1097/QAI.0000000000002042.
9
US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats.
Clin Infect Dis. 2019 Aug 16;69(5):884-889. doi: 10.1093/cid/ciz046.
10
Pre-exposure Prophylaxis for HIV Infection: Preventing Disease or Promoting Sexual Health?
J Community Health. 2019 Jun;44(3):423-427. doi: 10.1007/s10900-018-00616-3.
本文引用的文献
1
Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.
Am J Prev Med. 2013 Jan;44(1 Suppl 2):S86-90. doi: 10.1016/j.amepre.2012.09.035.
2
3
Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9.
4
Preexposure prophylaxis for HIV infection among African women.
N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.
5
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
N Engl J Med. 2012 Aug 2;367(5):423-34. doi: 10.1056/NEJMoa1110711. Epub 2012 Jul 11.
6
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524. Epub 2012 Jul 11.
7
HIV infection and HIV-associated behaviors among injecting drug users - 20 cities, United States, 2009.
MMWR Morb Mortal Wkly Rep. 2012 Mar 2;61(8):133-8.
8
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65-8.
9
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
Zotero 插件